» Articles » PMID: 18205705

Changes in Oxidant-antioxidant Status in Young Diabetic Patients from Clinical Onset Onwards

Overview
Journal J Cell Mol Med
Date 2008 Jan 22
PMID 18205705
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress has been implicated as a mechanism underlying hyperglycaemia-associated cellular damage and could play a role in the development of diabetes-related complications. This study aimed to evaluate the significance of changes in oxidant-antioxidant status in 176 child and adolescent diabetic patients at clinical onset, during disease progression and when early microvascular complications appeared. Indicative lipid and protein oxidation markers and antioxidant defence activity were measured in plasma and correlated with clinical data, diabetes duration, long-term glycometabolic control and serum lipids. Compared with their respective age-matched controls, diabetic patients had greater oxidative damage to lipids and proteins, demonstrated through the analysis of hydroperoxides, lipoperoxides and oxidation protein products, all of which were significantly raised at onset, decreased during the first 1.5 years of evolution and rose progressively thereafter. Plasma levels of oxidizable lipids were significantly associated with lipid and protein oxidation products. Overall, plasma antioxidant capacity was significantly and consistently lower from clinical onset onwards. These results suggest that insulin therapy in the first year improved metabolic and oxidant homeostasis and consequently hyperglycaemia-derived biomolecular oxidative damage. Diabetes-associated hyperlipidaemia is related to lipid and protein oxidation processes, which supports the concept of glucose toxicity and lipotoxicity being interrelated. The greatest increase in lipid and protein oxidative damage biomarkers in young diabetic patients with premature microangiopathy points to oxidative stress as a possible contributing mechanism of microvascular dysfunction. Consequently, tight lipid and glycometabolic control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.

Citing Articles

Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification.

Cavati G, Pirrotta F, Merlotti D, Ceccarelli E, Calabrese M, Gennari L Antioxidants (Basel). 2023; 12(4).

PMID: 37107303 PMC: 10135862. DOI: 10.3390/antiox12040928.


Changes in Oxidative and Nitrosative Stress Indicators and Vascular Endothelial Growth Factor After Maximum-Intensity Exercise Assessing Aerobic Capacity in Males With Type 1 Diabetes Mellitus.

Tota L, Matejko B, Morawska-Tota M, Pilch W, Mrozinska S, Palka T Front Physiol. 2021; 12:672403.

PMID: 34426731 PMC: 8379017. DOI: 10.3389/fphys.2021.672403.


Oxidative/Antioxidative Status in Patients after Myocardial Infarction and in Those without Cardiovascular Event Depending on Anthropometric Factors Defining Body Weight.

Nowicki G, Slusarska B, Prystupa A, Polak M, Czubaj-Kowal M, Rudnicka-Drozak E Int J Environ Res Public Health. 2019; 16(21).

PMID: 31652762 PMC: 6862597. DOI: 10.3390/ijerph16214077.


Total Oxidant and Antioxidant Status in Prepubertal Children with Obesity.

Rowicka G, Dylag H, Ambroszkiewicz J, Riahi A, Weker H, Chelchowska M Oxid Med Cell Longev. 2017; 2017:5621989.

PMID: 28904738 PMC: 5585688. DOI: 10.1155/2017/5621989.


Evaluation of oxidant-antioxidant status in overweight and morbidly obese Saudi children.

Albuali W World J Clin Pediatr. 2014; 3(1):6-13.

PMID: 25254179 PMC: 4145643. DOI: 10.5409/wjcp.v3.i1.6.


References
1.
Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

2.
Willems D, Dorchy H, Dufrasne D . Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis. 1998; 137 Suppl:S61-4. DOI: 10.1016/s0021-9150(97)00320-1. View

3.
Glazer A . Phycoerythrin fluorescence-based assay for reactive oxygen species. Methods Enzymol. 1990; 186:161-8. DOI: 10.1016/0076-6879(90)86106-6. View

4.
Steinberg D . Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002; 8(11):1211-7. DOI: 10.1038/nm1102-1211. View

5.
Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A . Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 2006; 10(2):389-406. PMC: 3933129. DOI: 10.1111/j.1582-4934.2006.tb00407.x. View